Case 3: Molecular Profile and Initiation of Therapy in ET

EP: 1.Case 1: Hydroxyurea-Resistant Polycythemia Vera (P. Vera)

EP: 2.Case 1: Diagnosis of P. Vera

EP: 3.Case 1: Risk Assessment in P. Vera

EP: 4.Case 1: Initial Treatment Options for Low Risk P. Vera

EP: 5.Case 1: Considerations for Cytoreductive Therapy in P. Vera

EP: 6.Case 1: Treatment Options after Hydroxyurea Failure in P. Vera

EP: 7.Case 1: Treatment Approaches for High Risk P. Vera

EP: 8.Case 1: Role of Symptomatic Improvement in Overall Outcome in MF

EP: 9.Case 2: High Risk Myelofibrosis (MF)

EP: 10.Case 2: Prognostic Models of MF

EP: 11.Case 2: Predictors of Response to Ruxolitinib in High Risk MF

EP: 12.Case 2: Safety and Efficacy of Ruxolitinib in High Risk MF

EP: 13.Case 2: Efficacy and Safety of Fedratinib in High Risk MF

EP: 14.Case 2: Considerations for Optimizing Therapy in High Risk MF

EP: 15.Case 3: Essential Thrombocythemia (ET)

EP: 16.Case 3: Risk Assessment in ET

EP: 17.Case 3: Individualized Therapy for ET

Now Viewing

EP: 18.Case 3: Molecular Profile and Initiation of Therapy in ET

EP: 19.Case 3: Front Line Therapy Options in ET

EP: 20.Case 3: Disease Progression and Transformation in ET

Ruben Mesa, MD: That was a wonderful discussion, Stephen. We’re building. We’ve been chatting all day about polycythemia vera and myelofibrosis. How does ET [essential thrombocythemia] fit into the mix? One of the big differences I see is that this is the only of the 3 that we’ve discussed where the molecular profile is a strong consideration in the current NCCN [National Comprehensive Cancer Network] guidelines regarding initiation of therapy. There’s a difference between the presence of a JAK2 mutation and the presence of CALR, with MPL being a relatively small percentage. Jamile, how does JAK2 vs CALR impact your treatment decisions in ET?

Jamile M. Shammo, MD: We all know that CALR-positive patients tend to do well. If I had a JAK2-positive patient with ET, I would be more cognizant of adding aspirin to their treatment. With CALR patients, I’d be less inclined—especially if they are younger—because I am impressed by the higher risk of bleeding that could come with CALR as their platelet count tends to be a little higher. That’s what I typically do in this patient population when it comes to their treatment.

Ruben Mesa, MD: I agree as well. There’s a difference between the two. I will point folks to the NCCN guidelines. It’s almost an asterisk, but it’s a key one, that low-risk patients who are symptomatic may benefit from cytoreduction. It’s wrong to think of ET as only a disease of thrombosis. There are a lot of individuals—not all; less than half—who can be quite symptomatic with the disease, and it’s only better if they are cytoreduced. When it comes to asymptomatic patients who are very low risk, absolutely. But be mindful of those symptoms. They are an important part of the equation.

This transcript has been edited for clarity.